Total Products under this Category: 175
Last updated: November 12, 2026
Why You Can Trust G2's Software Rankings:
G2's software rankings are built on verified user reviews, rigorous moderation, and a consistent research methodology maintained by a team of analysts and data experts. Each product is measured using the same transparent criteria, with no paid placement or vendor influence. While reviews reflect real user experiences, which can be subjective, they offer valuable insight into how software performs in the hands of professionals. Together, these inputs power the G2 Score, a standardized way to compare tools within every category.
FCS Express works hard to turn your flow cytometry data into results, so you don't have to. FCS Express can rapidly analyze vast amounts of data, with industry leading flow cytometry tools, but we recognize that is only the beginning of the scientific journey.
A health-tech platform that offers small-molecule precision medicine for cancer patients, allowing medical professionals to change the trajectory of how to treat diseases.
GEn1E is a clinical-stage multi-target AI platform. They develop novel, next-gen, immunomodulators for rare & inflammatory diseases.
Connect G2 to Claude or ChatGPT for answers grounded in G2's trusted reviews, comparisons, and pricing from real user insights.
Automates time consuming and repetitive tasks during image analysis set-up. Increases reproducibility and detects complex phenotypes by eliminating the biased selection of handcrafted features. Saves time by quickly being re-applied in different experimental settings. Seamlessly integrates with Genedata Screener for image data analysis.
Genesis Therapeutics is a pioneering biotechnology company that leverages its proprietary Generative AI for Molecular Design (GEMS) platform to revolutionize drug discovery. By integrating advanced artificial intelligence with physics-based simulations, Genesis Therapeutics aims to develop highly potent and selective small-molecule therapeutics targeting complex and traditionally challenging biological structures. Key Features and Functionality: - GEMS Platform: A state-of-the-art AI-driven system that combines proprietary AI and physics research to identify and optimize drug candidates with unprecedented potency and selectivity. - Oncology Pipeline: Development of first- or best-in-class small molecules targeting difficult biological targets to advance cancer treatment. - Immunology Pipeline: Creation of first-in-class small molecules for well-validated and novel immunology targets, aiming to provide oral treatment options for autoimmune disorders. - Strategic Partnerships: Collaborations with industry leaders like Incyte and Gilead to enhance the impact of the GEMS platform in drug discovery. Primary Value and Problem Solved: Genesis Therapeutics addresses the critical challenge of developing effective treatments for diseases with complex and difficult-to-target biological structures. By harnessing the power of AI and physics-based simulations through their GEMS platform, the company accelerates the drug discovery process, leading to the creation of highly potent and selective therapeutics. This approach not only enhances the efficiency of drug development but also opens new avenues for treating conditions that have been historically challenging to address with traditional methods.
Gero is a biotechnology company dedicated to developing therapeutics that target the fundamental physics of aging, aiming to significantly extend healthy human lifespan. By integrating principles from theoretical physics, advanced biology, and artificial intelligence, Gero seeks to intercept functional decline before it manifests as disease, thereby restoring resilience and potentially doubling healthy human lifespan within a single generation. Key Features and Functionality: - Foundational Models of Human Health: Gero's AI is trained on extensive real-world datasets, encompassing over 100 million patient records. This enables the mapping of aging trajectories across diverse populations, uncovering causal pathways that drive both diseases and the aging process itself. - Physics-Informed, Interpretable AI Models: Grounded in thermodynamics, these models distinguish between irreversible aging processes and reversible disease mechanisms. This approach identifies targets that can restore systemic resilience and modulate the rate of aging and disease progression. - Balanced Business Model: Gero collaborates with pharmaceutical companies on high-value, age-related indications while simultaneously advancing scientifically robust anti-aging interventions in-house. This strategy mitigates scientific risk and accelerates the impact on patient health. Primary Value and Solutions Provided: Gero addresses the interconnected nature of age-related diseases by focusing on the underlying aging process, which has traditionally constrained drug discovery efforts. By emphasizing the irreversible aspects of aging and highlighting the reversible components of diseases, Gero's approach distinguishes between these phenomena. Through the integration of Large Health Models with comprehensive molecular data, Gero unveils novel treatments for chronic age-related diseases, both independently and in collaboration with pharmaceutical partners. This innovative methodology offers a new pathway to develop therapies that not only treat symptoms but also target the root causes of aging, aiming to extend the period of healthy, disease-free life.
CRISPR Accelerates Drug Discovery From Target ID Through Preclinical Development
Healnet enables highly parallel and large-scale rare disease drug discovery, significantly reducing time, cost and risk.
Iambic Therapeutics is a biotechnology company that leverages a physics-informed, AI-driven platform to revolutionize drug discovery and development. By integrating advanced artificial intelligence with high-throughput experimental automation, Iambic accelerates the identification and optimization of novel therapeutics, aiming to address unmet medical needs across various diseases.
